Journal Article (Review Article) DZNE-2020-00294

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Neuroenhancement and mood enhancement-Physiological and pharmacodynamical background | Hirndoping-Neuroenhancement Pharmakodynamik des Neuroenhancement und physiologische Grundlagen

 ;  ;

2017
Wiss. Verl.-Ges. : Dt. Apotheker Verl. Stuttgart

Medizinische Monatsschrift für Pharmazeuten 40(4), 154 - 166 ()

Abstract: Pharmacological neuroenhancement and mood enhancement are gaining tremendous importance in society. The main motivation for neuroenhancement and mood enhancement is the anticipated increase in attention and vigilance, better performance in learning and memory and mood stability to meet the complex demands of an exacerbating meritocracy. Most users apply drugs originally designated for attention disorders, sleep disorders or dementia. Application of related drugs in terms of enhancement strategies in healthy individuals is off-label per se, the acquisition and distribution illegal. Here, we first provide an overview of the basic physiological mechanisms underlying vigilance, learning and memory, and emotional states. We then present the different pharmacological classes, i. a. purines and methylxanthines, phenylethylamine, modafinil, nootropics and antidepressants and elaborate their pharmacodynamics profile. Special attention will be paid to the norepinephrine/dopamine and cholinergic receptors and transporter systems but also to functional interaction with adenosine, serotonine and the glutamate receptor systems. Metaanalysis revealed that efficacy reported in, e. g. ADHD or dementia patients cannot be translated to healthy individuals. A validated positive effect on attention and vigilance has only been reported for some phenylethylamines and modafinil. It is likely that new developments, particularly in the field of antidementives will dramatically enhance neuroenhancement and mood enhancement. Drug regulatory actions, public and political discussions are necessary to meet the ethical and legal challenges of neuroenhancement and mood enhancement in the future.

Classification:

Contributing Institute(s):
  1. Translational Biogerontology (AG Ehninger)
Research Program(s):
  1. 342 - Disease Mechanisms and Model Systems (POF3-342) (POF3-342)

Appears in the scientific report 2017
Database coverage:
Medline ; SCOPUS
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > BN DZNE > BN DZNE-AG Ehninger
Public records
Publications Database

 Record created 2020-06-30, last modified 2025-09-01



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)